The scramble to research the novel coronavirus has exposed weaknesses in the vetting of healthcare data being supplied by a growing number of US firms, a flaw that forced two of the most respected medical journals to pull studies last week.
The drug hydroxychloroquine is displayed by a pharmacist. (File photo: Reuters)
‘Reviewing our procedures’
A researcher works inside a laboratory of Chulalongkorn University during the development of an mRNA type vaccine candidate for the coronavirus disease (COVID-19) in Bangkok, Thailand, May 25, 2020. (Reuters)